Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Produc… Read more
Chengdu Kanghua Biological Products (300841) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.026x
Based on the latest financial reports, Chengdu Kanghua Biological Products (300841) has a cash flow conversion efficiency ratio of 0.026x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥92.89 Million) by net assets (CN¥3.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chengdu Kanghua Biological Products - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Chengdu Kanghua Biological Products's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chengdu Kanghua Biological Products Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chengdu Kanghua Biological Products ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crayon Group Holding ASA
PINK:CRAYF
|
0.639x |
|
Chongqing Department Store Co Ltd
SHG:600729
|
0.066x |
|
Attendo AB (publ)
ST:ATT
|
0.174x |
|
Xinyu Iron & Steel Co Ltd
SHG:600782
|
0.050x |
|
FPT Digital Retail JSC
VN:FRT
|
0.039x |
|
Xiamen Wanli Stone Stock Co Ltd
SHE:002785
|
0.242x |
|
KAGA EL. CO. LTD
F:9V2
|
N/A |
|
Inari Amertron Bhd
KLSE:0166
|
0.027x |
Annual Cash Flow Conversion Efficiency for Chengdu Kanghua Biological Products (2015–2024)
The table below shows the annual cash flow conversion efficiency of Chengdu Kanghua Biological Products from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.45 Billion | CN¥572.24 Million | 0.166x | +1.62% |
| 2023-12-31 | CN¥3.51 Billion | CN¥573.98 Million | 0.163x | +157.64% |
| 2022-12-31 | CN¥3.08 Billion | CN¥194.99 Million | 0.063x | +29.90% |
| 2021-12-31 | CN¥2.67 Billion | CN¥130.33 Million | 0.049x | -73.93% |
| 2020-12-31 | CN¥1.97 Billion | CN¥369.56 Million | 0.187x | -41.14% |
| 2019-12-31 | CN¥574.65 Million | CN¥182.73 Million | 0.318x | +103.86% |
| 2018-12-31 | CN¥367.70 Million | CN¥57.35 Million | 0.156x | -67.34% |
| 2017-12-31 | CN¥188.37 Million | CN¥89.96 Million | 0.478x | +1838.25% |
| 2016-12-31 | CN¥-96.21 Million | CN¥2.64 Million | -0.027x | +56.55% |
| 2015-12-31 | CN¥-102.87 Million | CN¥6.51 Million | -0.063x | -- |